© Copyright RiverVest® All Rights Reserved.
/ PORTFOLIO
San Carlos, CA
Glycomine is a clinical-stage biopharmaceutical company that is advancing treatments for serious rare diseases with no other therapeutic options. The Company’s lead investigational drug candidate GLM101 is a mannose-1-phosphate replacement therapy in development to treat PMM2-CDG.